Brief: Kiromic Biopharma Reports Favorable Deltacel Preclinical Pharmacology Results
28/02/2023 13:17
Feb 28 (Reuters) - Kiromic Biopharma Inc KRBP.O :
* KIROMIC BIOPHARMA REPORTS FAVORABLE DELTACEL™ PRECLINICAL
PHARMACOLOGY RESULTS
* IND SUBMISSION AND ACTIVATION OF CLINICAL TRIAL PROCESS ON
TRACK
FOR Q1 AND Q2 OF THIS YEAR, RESPECTIVELY
* DELTACEL™ WAS WELL TOLERATED IN MICE, EVEN WHEN GIVEN AS
PART OF
A COMBINATION THERAPY THAT FURTHER BOOSTED ITS POTENCY
Source text for Eikon: ID:nBw3XJwyra
Further company coverage: KRBP.O
Recent news on Kiromic Biopharma
See all newsBrief: Kiromic Biopharma Files For Offering Up To 1 Million Units
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site